Literature DB >> 21332346

Norcantharidin attenuates tubulointerstitial fibrosis in rat models with diabetic nephropathy.

Ying Li1, Qiong Chen, Fu-You Liu, You-Ming Peng, Tao Hou, Shao-Bin Duan, Jun Li, Jun-Hui Luo, Lin Sun, Guang-Hui Ling.   

Abstract

OBJECTIVE: To investigate the effects of norcantharidin (NCTD) on tubulointerstitial fibrosis of diabetic nephropathy (DN) in streptozotocin-induced rat model.
METHODS: Sprague-Dawley rats were randomly divided into control group, model group, low-dose NCTD (0.05 mg/kg/day) group, and high-dose NCTD (0.1 mg/kg/day) group. The model group was induced by injection intraperitoneally with 30 mg/kg streptozotocin in 0.1 mol/L sodium citrate solution (pH 4.5), after high-calorie foods were given for 2 months. NCTD was administered daily after the DN rat model was built. Rats were sacrificed at the end of the third and the eighth week; renal fibrosis and the expression of FN, collagen IV, TGF-β1, and calcineurin (CaN) were detected by Masson and immunohistochemistry staining, respectively.
RESULTS: Tubulointerstitial fibrosis was observed in DN rats, this kind of pathological changes was ameliorated in NCTD treatment group (p < 0.05). The expressions of FN, collagen IV, and TGF-β1 protein increased in the tubulointerstitial field of DN rats compared with the rats in control group. NCTD treatment could dose-dependently decrease their expression and reverse the fibrotic degree (p < 0.05). Meanwhile, the expression of CaN was detected in tubular fields of normal kidney and increased in the tubulointerstitial field in DN rats. However, NCTD downregulated its expression in a dose-dependent manner (p < 0.05).
CONCLUSIONS: NCTD could downregulate FN, collagen IV, and TGF-β1 expression in tubulointerstitial fields and attenuate tubulointerstitial fibrosis in the early stage of DN rats. NCTD also alleviated the expression of CaN in tubules in DN. The relationship between the role of NCTD's anti-tubulointerstitial fibrosis and its inhibition to CaN expression remains to be further elucidated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21332346     DOI: 10.3109/0886022X.2011.553305

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  10 in total

Review 1.  Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis.

Authors:  Ying Li; Yan Ge; Fu You Liu; You Ming Peng; Lin Sun; Jun Li; Qiong Chen; Yan Sun; Kun Ye
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

2.  Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats.

Authors:  Michaele B Manigrasso; R Taylor Sawyer; Zachary M Hutchens; Elizabeth R Flynn; Christine Maric-Bilkan
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-01

3.  Antimetastatic effects of norcantharidin on hepatocellular carcinoma cells by up-regulating FAM46C expression.

Authors:  Xu-Ying Wan; Xiao-Feng Zhai; Yi-Ping Jiang; Ting Han; Qiao-Yan Zhang; Hai-Liang Xin
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

4.  Norcantharidin inhibits renal interstitial fibrosis by downregulating PP2Ac expression.

Authors:  Tao Hou; Zheng Xiao; Ying Li; Yan-Hua You; Hua Li; Yu-Ping Liu; Yi-Yun Xi; Jun Li; Shao-Bin Duan; Hong Liu; Lin Sun; You-Ming Peng; Fu-You Liu
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

5.  Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors.

Authors:  Chunbo Zou; Rujuan Xie; Yushi Bao; Xiaogang Liu; Manshu Sui; Suhong M; Shuang Li; Huiqing Yin
Journal:  Endocrine       Date:  2013-03-07       Impact factor: 3.633

6.  Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition.

Authors:  Ying Li; Yan Sun; Fuyou Liu; Lin Sun; Jun Li; Shaobin Duan; Hong Liu; Youming Peng; Li Xiao; Yuping Liu; Yiyun Xi; Yanhua You; Hua Li; Min Wang; Shuai Wang; Tao Hou
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

Review 7.  Norcantharidin, derivative of cantharidin, for cancer stem cells.

Authors:  Chen-Hsi Hsieh; K S Clifford Chao; Hui-Fen Liao; Yu-Jen Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-02       Impact factor: 2.629

8.  Effect of norcantharidin on the proliferation, apoptosis, and cell cycle of human mesangial cells.

Authors:  Kun Ye; Qiaoyu Wei; Zhifeng Gong; Yunfeng Huang; Hong Liu; Ying Li; Xiaomei Peng
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

9.  Therapeutic induction of Bcl2-associated athanogene 3-mediated autophagy in idiopathic pulmonary fibrosis.

Authors:  Shashipavan Chillappagari; Julian Schwarz; Vidyasagar Kesireddy; Jessica Knoell; Martina Korfei; Konrad Hoetzenecker; M Lienhard Schmitz; Christian Behl; Saverio Bellusci; Andreas Guenther; Poornima Mahavadi
Journal:  Clin Transl Med       Date:  2022-07

10.  Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis.

Authors:  Amit Sharma; Md Abdul Hye Khan; Scott P Levick; Kin Sing Stephen Lee; Bruce D Hammock; John D Imig
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.